001     839920
005     20210129231710.0
024 7 _ |a 10.1016/j.ejpb.2017.09.018
|2 doi
024 7 _ |a 0939-6411
|2 ISSN
024 7 _ |a 1873-3441
|2 ISSN
024 7 _ |a pmid:28986295
|2 pmid
024 7 _ |a WOS:000414621100011
|2 WOS
024 7 _ |a altmetric:30232873
|2 altmetric
037 _ _ |a FZJ-2017-07498
082 _ _ |a 610
100 1 _ |a Lucio, David
|0 0000-0002-4071-4767
|b 0
|e Corresponding author
245 _ _ |a Optimization and evaluation of zein nanoparticles to improve the oral delivery of glibenclamide. In vivo study using C. elegans
260 _ _ |a New York, NY [u.a.]
|c 2017
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1512479589_31848
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The aim of this work was to evaluate the capability of zein nanoparticles as oral carriers for glibenclamide (GB). Nanoparticles were prepared by a desolvation procedure in the presence of lysine as stabilizer. A central composite design was used to optimize this preparative process. Under the selected conditions, nanoparticles displayed a size of about 190 nm, a surface charge of −37 mV and a payload of 45 µg GB/mg. Small-angle neutron scattering and X-ray diffraction techniques suggested an internal fractal-like structure, based on the repetition of spherical blocks of zein units (about 20 nm) grouped to form the nanoparticles. This structure, stabilized by lysine molecules located at the surface, would determine the release of GB (molecularly trapped into the nanoparticles) by a pure diffusion mechanism. Moreover, GB-loaded nanoparticles induced a significant hypolipidemic effect with a reduction of about 15% in the fat content of C. elegans worms. In addition, did not induce any significant modification in the lifespan of worms. In summary, the employment of zein nanoparticles as delivery systems of glibenclamide may be an interesting approach to develop new oral formulations of this antidiabetic drug.
536 _ _ |a 6G4 - Jülich Centre for Neutron Research (JCNS) (POF3-623)
|0 G:(DE-HGF)POF3-6G4
|c POF3-623
|f POF III
|x 0
536 _ _ |0 G:(DE-HGF)POF3-6G15
|f POF III
|x 1
|c POF3-6G15
|a 6G15 - FRM II / MLZ (POF3-6G15)
588 _ _ |a Dataset connected to CrossRef
650 2 7 |a Medicine
|0 V:(DE-MLZ)SciArea-190
|2 V:(DE-HGF)
|x 0
650 1 7 |a Health and Life
|0 V:(DE-MLZ)GC-130-2016
|2 V:(DE-HGF)
|x 0
693 _ _ |a Forschungs-Neutronenquelle Heinz Maier-Leibnitz
|e KWS-2: Small angle scattering diffractometer
|f NL3ao
|1 EXP:(DE-MLZ)FRMII-20140101
|0 EXP:(DE-MLZ)KWS2-20140101
|5 EXP:(DE-MLZ)KWS2-20140101
|6 EXP:(DE-MLZ)NL3ao-20140101
|x 0
700 1 _ |a Martínez-Ohárriz, María Cristina
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Jaras, Gonzalo
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Aranaz, Paula
|0 P:(DE-HGF)0
|b 3
700 1 _ |a González-Navarro, Carlos J.
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Radulescu, Aurel
|0 P:(DE-Juel1)130905
|b 5
|u fzj
700 1 _ |a Irache, Juan M.
|0 P:(DE-HGF)0
|b 6
773 _ _ |a 10.1016/j.ejpb.2017.09.018
|g Vol. 121, p. 104 - 112
|0 PERI:(DE-600)1483524-1
|p 104 - 112
|t European journal of pharmaceutics and biopharmaceutics
|v 121
|y 2017
|x 0939-6411
856 4 _ |u https://juser.fz-juelich.de/record/839920/files/1-s2.0-S0939641117309268-main.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/839920/files/1-s2.0-S0939641117309268-main.gif?subformat=icon
|x icon
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/839920/files/1-s2.0-S0939641117309268-main.jpg?subformat=icon-1440
|x icon-1440
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/839920/files/1-s2.0-S0939641117309268-main.jpg?subformat=icon-180
|x icon-180
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/839920/files/1-s2.0-S0939641117309268-main.jpg?subformat=icon-640
|x icon-640
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/839920/files/1-s2.0-S0939641117309268-main.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:839920
|p VDB:MLZ
|p VDB
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)130905
913 1 _ |a DE-HGF
|b Forschungsbereich Materie
|l Von Materie zu Materialien und Leben
|1 G:(DE-HGF)POF3-620
|0 G:(DE-HGF)POF3-623
|2 G:(DE-HGF)POF3-600
|v Facility topic: Neutrons for Research on Condensed Matter
|9 G:(DE-HGF)POF3-6G4
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
913 1 _ |a DE-HGF
|9 G:(DE-HGF)POF3-6G15
|x 1
|4 G:(DE-HGF)POF
|v FRM II / MLZ
|1 G:(DE-HGF)POF3-6G0
|0 G:(DE-HGF)POF3-6G15
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-600
|b Forschungsbereich Materie
|l Großgeräte: Materie
914 1 _ |y 2017
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J PHARM BIOPHARM : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)JCNS-FRM-II-20110218
|k JCNS (München) ; Jülich Centre for Neutron Science JCNS (München) ; JCNS-FRM-II
|l JCNS-FRM-II
|x 0
920 1 _ |0 I:(DE-Juel1)JCNS-1-20110106
|k Neutronenstreuung ; JCNS-1
|l Neutronenstreuung
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)JCNS-FRM-II-20110218
980 _ _ |a I:(DE-Juel1)JCNS-1-20110106
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21